High Prevalence of Mutations at Codon 249 of the P53 Gene in Hepatocellular Carcinomas from Senegal

Overview

Journal Br J Cancer

Specialty Oncology

Date 1993 Jun 1

PMID 8390289

Citations 18

Authors

P Coursaget

N Depril

M Chabaud

R Nandi

V Mayelo

P LeCann

B Yvonnet

Affiliations

Soon will be listed here.

Abstract

In hepatocellular carcinoma, mutation within the p53 gene occurs mainly at codon 249 and its frequency has been associated with exposure to aflatoxin. As Senegal is a country where liver cancer incidence is one of the highest in the world and where people are highly exposed to aflatoxin, we screened 15 liver cancer samples from this country for mutation at codon 249 of the p53 gene. Non-tumoral DNA from the patients showed a wild type genotype. Mutation at codon 249 of the p53 gene was detected in 10 of the 15 tumour tissues tested (67%). This frequency of mutation in codon 249 of the p53 gene is the highest described. These results confirmed that there is an association between countries of high aflatoxin intake and a high frequency of mutation in codon 249 of p53 gene, and that HBV alone does not contribute to these base changes.

Citing Articles

Aflatoxin biocontrol effectiveness in the real world-Private sector-led efforts to manage aflatoxins in Nigeria through biocontrol-centered strategies.

Ola O, Ogedengbe O, Raji T, Eze B, Chama M, Ilori O Front Microbiol. 2022; 13:977789.

PMID: 36118233 PMC: 9478371. DOI: 10.3389/fmicb.2022.977789.

A Review of Cancer Genetics and Genomics Studies in Africa.

Rotimi S, Rotimi O, Salhia B Front Oncol. 2021; 10:606400.

PMID: 33659210 PMC: 7917259. DOI: 10.3389/fonc.2020.606400.

Analysis of aflatoxin signature mutation in hepatocellular carcinomas from Guatemala: A cross-sectional study (2016-2017).

Alvarez C, Ortiz J, Bendfeldt-Avila G, Xie Y, Wang M, Wu D Health Sci Rep. 2020; 3(2):e155.

PMID: 32382660 PMC: 7202218. DOI: 10.1002/hsr2.155.

"Ground-Truthing" Efficacy of Biological Control for Aflatoxin Mitigation in Farmers' Fields in Nigeria: From Field Trials to Commercial Usage, a 10-Year Study.

Bandyopadhyay R, Atehnkeng J, Ortega-Beltran A, Akande A, Falade T, Cotty P Front Microbiol. 2019; 10:2528.

PMID: 31824438 PMC: 6882503. DOI: 10.3389/fmicb.2019.02528.

It takes a team: a gain-of-function story of p53-R249S.

Wang H, Liao P, Zeng S, Lu H J Mol Cell Biol. 2019; 11(4):277-283.

PMID: 30608603 PMC: 6487778. DOI: 10.1093/jmcb/mjy086.

References

Hsu I, Metcalf R, Sun T, Welsh J, Wang N, Harris C . Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991; 350(6317):427-8. DOI: 10.1038/350427a0. View

Harris A . Cancer genes. Telling changes of base. Nature. 1991; 350(6317):377-8. DOI: 10.1038/350377a0. View

Hollstein M, Sidransky D, Vogelstein B, Harris C . p53 mutations in human cancers. Science. 1991; 253(5015):49-53. DOI: 10.1126/science.1905840. View

Hayward N, Walker G, GRAHAM W, Cooksley E . Hepatocellular carcinoma mutation. Nature. 1991; 352(6338):764. DOI: 10.1038/352764a0. View

Murakami Y, Hayashi K, Hirohashi S, Sekiya T . Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 1991; 51(20):5520-5. View

Zagursky R, Conway P, Kashdan M . Use of 33P for Sanger DNA sequencing. Biotechniques. 1991; 11(1):36, 38. View

Fujimoto Y, Hampton L, Luo L, Wirth P, Thorgeirsson S . Low frequency of p53 gene mutation in tumors induced by aflatoxin B1 in nonhuman primates. Cancer Res. 1992; 52(4):1044-6. View

Sears L, Moran L, Kissinger C, Creasey T, Perry-OKeefe H, Roskey M . CircumVent thermal cycle sequencing and alternative manual and automated DNA sequencing protocols using the highly thermostable VentR (exo-) DNA polymerase. Biotechniques. 1992; 13(4):626-33. View

Diop B, Denis F, Barin F, Perrin J, Chiron J, Goudeau A . Epidemiology of primary hepatocellular carcinoma in Senegal. Prog Med Virol. 1981; 27:35-40. View

10.

Coursaget P, Yvonnet B, Barres J, Perrin J, Tortey E, Diop B . [Hepatitis B and primary cancer of the liver in intertropical Africa]. Rev Epidemiol Sante Publique. 1985; 33(4-5):267-75. View

11.

Thiers V, Nakajima E, Kremsdorf D, Mack D, Schellekens H, Driss F . Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet. 1988; 2(8623):1273-6. DOI: 10.1016/s0140-6736(88)92891-7. View

12.

Dykes D . The use of biotinylated DNA probes in parentage testing: non-isotopic labeling and non-toxic extraction. Electrophoresis. 1988; 9(8):359-68. DOI: 10.1002/elps.1150090803. View

13.

Wild C, Jiang Y, Allen S, Jansen L, Hall A, Montesano R . Aflatoxin-albumin adducts in human sera from different regions of the world. Carcinogenesis. 1990; 11(12):2271-4. DOI: 10.1093/carcin/11.12.2271. View

14.

Sell S, Hunt J, Dunsford H, Chisari F . Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res. 1991; 51(4):1278-85. View

15.

Hosono S, Lee C, Chou M, Yang C, Shih C . Molecular analysis of the p53 alleles in primary hepatocellular carcinomas and cell lines. Oncogene. 1991; 6(2):237-43. View

16.

Bressac B, Kew M, Wands J, Ozturk M . Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991; 350(6317):429-31. DOI: 10.1038/350429a0. View